- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Snapshot for ViroPharma Inc (VPHM)
| Open: | 20.2600 | Day's Range: | 20.0310 - 20.7000 | Volume: | 479,897 | Bid: | 20.3700 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 20.1200 | 52wk Range: | 14.6200 - 33.1692 | 1-Yr Rtn: | +8.11% | Ask: | 20.3800 |
Key Statistics for VPHM
| Current P/E Ratio (ttm) | 13.0705 |
|---|---|
| Estimated P/E (12/2012) | 24.2449 |
| Earnings Per Share (USD) (ttm) | 1.5600 |
| Est. EPS (USD) (12/2012) | 0.8410 |
| Est. PEG Ratio | 3.0306 |
| Market Cap (M USD) | 1,421.81 |
| Shares Outstanding (M) | 69.73 |
| Enterprise Value (M USD) (ttm) | 1,103.91 |
| Enterprise Value/EBITDA (ttm) | 4.68 |
| Price/Book (mrq) | 1.6202 |
| Price/Sale (ttm) | 2.6750 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 07/27/2012 |
More VPHM Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for VPHM
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for VPHM
ViroPharma Incorporated is a biopharmaceutical company committed to the commercialization, development, and discovery of new medicines. The Company's products include a treatment for prophylaxis of hereditary angioedema as well a capsules for the treatment of antibiotic associated pseudomembranous colitis caused by Clostridium difficile infection (CDI) and enterocolitis.
| Vincent J Milano "Vin"Chairman/President/CEO | Charles A Rowland JrVP/CFO |
| Daniel B SolandVP/COO | Colin BroomVP/Chief Scientific Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page